Tumor Marker Characterization in the Serially Transplantable PC-EW Human Prostatic Carcinoma Line in Nude Mice

  • Z. Csapo
  • K. M. Schrott
  • R. Walther
Conference paper


Prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) are organ- specific substances. Although neither PAP nor PSA are tumor specific, their serum values in patients with prostate cancer frequently appear markedly elevated as compared with the values of healthy subjects or patients affected by malignancies of non- prostatic origin (Foti et al. 1977; Wang et al. 1979; Kuriyama et al. 1982). Since successful therapy causes a decrease in the serum levels of both substances, they can be regarded as useful tumor markers. Clinical findings during the past few years show that serum PSA can frequently be raised when the serum PAP is normal (Chu and Murphy 1986; Siddal et al. 1986; Ahmann and Schifman 1987). Preliminary studies in patients with prostate cancer have shown a correlation between the frequency of pathological PSA levels and disease stage, grade, and activity (Csapo et al. 1987). However, little data are available for comparing the indicator value of PSA with PAP.


Tumor Volume Prostate Specific Antigen Prostate Specific Antigen Level Prostatic Acid Phosphatase Prostate Specific Antigen Serum Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmann FR, Schifman RB (1987) Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurement in metastatic prostatic cancer. J Urol 137: 431–434PubMedGoogle Scholar
  2. Chu TM, Murphy GP (1986) What’s new in tumor markers for prostate cancer? Urology 27: 487–491PubMedCrossRefGoogle Scholar
  3. Csapo Z, Sigel A, Brand K (1987) Significance of prostatic acid phosphatase (PAP) and prostate specific antigen ( PSA) in the diagnosis and follow-up of prostate cancer. Urologe B 27: 238–245Google Scholar
  4. Foti AG, Cooper JF, Herschmann H, Malvarez RR (1977) Detection of prostate cancer by solid phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 297: 1357–1361PubMedCrossRefGoogle Scholar
  5. Höhn W, Schröder FH, Riemann JF, Jöbsis AC, Hermanek P (1980) Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1: 95–104CrossRefGoogle Scholar
  6. Höhn W, Wagner M, Riemann JF, Hermanek P, Williams E, Walther R, Schrüffer R (1984) Prostatic adenocarcinoma PC-EW. A new human tumor line transplantable in nude mice. Prostate 5: 445–452Google Scholar
  7. Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero L, Inaji H, Loor RM, Lin MF, Nishiura T, Slack NH, Murphy GP, Chu TM (1982) Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 68: 99–105PubMedGoogle Scholar
  8. Siddal JK, Cooper EH, Newling DWW, Robinson MRG, Whelan P (1986) An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol 12: 123–130Google Scholar
  9. van Steenbrugge GJ, Blankenstein MA, Bolt-de Vries J, Romijn JC, Schröder FH, Vihko P (1983) Effect of hormone treatment on prostatic acid phosphatase in a serially transplantable human prostatic adenocarcinoma (PC-82). J Urol 129: 630–633PubMedGoogle Scholar
  10. Wang MP, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17: 159–163PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Z. Csapo
  • K. M. Schrott
  • R. Walther
    • 1
  1. 1.Department of Urology, Medical FacultyUniversity of Erlangen-NürnbergErlangenGermany

Personalised recommendations